Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Total Debt (2016 - 2025)

Historic Total Debt for BioCorRx (BICX) over the last 11 years, with Q3 2025 value amounting to $69803.0.

  • BioCorRx's Total Debt fell 9425.48% to $69803.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $69803.0, marking a year-over-year decrease of 9425.48%. This contributed to the annual value of $71029.0 for FY2024, which is 9289.06% down from last year.
  • Per BioCorRx's latest filing, its Total Debt stood at $69803.0 for Q3 2025, which was down 9425.48% from $71029.0 recorded in Q4 2024.
  • In the past 5 years, BioCorRx's Total Debt registered a high of $3.1 million during Q2 2022, and its lowest value of $69803.0 during Q3 2025.
  • Moreover, its 5-year median value for Total Debt was $999088.0 (2023), whereas its average is $1.3 million.
  • In the last 5 years, BioCorRx's Total Debt plummeted by 9557.07% in 2021 and then soared by 125286.12% in 2023.
  • BioCorRx's Total Debt (Quarter) stood at $105880.0 in 2021, then crashed by 30.25% to $73850.0 in 2022, then skyrocketed by 1252.86% to $999088.0 in 2023, then crashed by 92.89% to $71029.0 in 2024, then dropped by 1.73% to $69803.0 in 2025.
  • Its Total Debt stands at $69803.0 for Q3 2025, versus $71029.0 for Q4 2024 and $1.2 million for Q3 2024.